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Podocyte injury and loss contribute to progressive
glomerulosclerosis. Peroxisome proliferator-activated
receptor-c (PPAR-c) is a nuclear hormone receptor, which we
have found to be increased in podocytes in a variety of
kidney diseases. It is not known if PPAR-c contributes to renal
injury or if it serves as a countermeasure to limit renal injury
during disease progression. We tested these possibilities
utilizing the puromycin aminonucleoside (PAN) model of
renal injury in immortalized mouse podocytes. The cultured
podocytes expressed PPAR-c mRNA at baseline but this was
decreased by PAN. Pioglitazone, a pharmacologic agonist of
PPAR-c, increased both PPAR-c mRNA and activity in injured
podocytes, as assessed by a reporter plasmid assay. Further,
pioglitazone significantly decreased PAN-induced podocyte
apoptosis and necrosis while restoring podocyte
differentiation. The PPAR-c agonist significantly restored
expression of the cyclin-dependent kinase inhibitor p27 and
the antiapoptotic molecule Bcl-xL while significantly
decreasing proapoptotic caspase-3 activity. Pioglitazone
tended to decrease PAN-induced transforming growth factor-
b (TGF-b) mRNA expression. Our study shows that PPAR-c is
normally expressed by podocytes and its activation is
protective against PAN-induced apoptosis and necrosis. We
postulate that this protective effect may be mediated in part
by effects on p27 and TGF-b expression.
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Peroxisome proliferator-activated receptor-g (PPAR-g) is a
member of the nuclear hormone receptor superfamily, and a
pharmacological target for the antidiabetic thiazolidine-
diones.1 PPAR-g contains both ligand- and DNA-binding
domains. PPAR-g forms a heterodimeric complex with
retinoic X receptor, translocates to the nucleus, and binds
to defined PPAR response elements in the promoter regions
of specific target genes. PPAR-g agonists enhance insulin
sensitivity, decrease hepatic glucose production, and decrease
low-density lipoprotein levels, and thereby ameliorate both
the dysmetabolic state of diabetes mellitus and its complica-
tions, including diabetic nephropathy.1 PPAR-g is widely
expressed and has a variable role in cell-cycle regulation
depending on cell type. PPAR-g tends to inhibit cell growth
and promotes differentiation, decreases inflammation, and
inhibits extracellular cellular matrix accumulation.
Podocytes are terminally differentiated and highly specia-
lized cells. Podocyte injury with subsequent depletion is a key
component of progressive glomerulosclerosis, regardless of
the nature of the initial insult. Mature podocytes have limited
ability to proliferate following injury, linked to high
expression of the cyclin-dependent kinase inhibitors (CKIs)
p27 and p57, which appear to be rate-limiting for podocytes
to reenter the cell cycle.2 Another CKI, p21, appears to be
necessary for development of sclerosis after 5/6 nephrectomy
in mice.3 Apoptosis may play an important role in loss of
podocytes after injury. Indeed, apoptosis is increased in
human focal segmental glomerulosclerosis (FSGS).4 Thiazo-
lidinediones may promote or protect against apoptosis,
depending on cell type and nature of injury.5–7 Numerous
other factors, including transforming growth factor-b (TGF-
b), may also promote podocyte apoptosis.8 In early-stage
diabetic nephropathy in humans, treatment with a PPAR-g
agonist reduced podocyturia, likely reflecting amelioration of
podocyte injury, detachment, and possibly apoptosis.9 PPAR-
g agonist also attenuated tubular epithelial cell apoptosis in
vitro.10 We previously showed in vivo that thiazolidinedione
ameliorated injury both in the remnant kidney and in PAN
nephropathy models, associated with increased PPAR-g
expression in podocytes.11,12 We also observed increased
podocyte PPAR-g in human diabetic nephropathy, hyperten-
sive nephrosclerosis, and chronic allograft nephropathy.13–16
The association of increased PPAR-g with sclerotic injury
could suggest that PPAR-g may induce podocyte injury and
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cause glomerulosclerosis. Alternatively, increased PPAR-g
expression in podocytes after injury may be a counter-
regulatory beneficial response. We therefore investigated the
effects of PPAR-g agonist on podocyte injury induced by
PAN. We further examined effects of PPAR-g activation on
cell-cycle proteins, apoptosis markers, and TGF-b.
RESULTS
Podocyte morphologic changes
Treatment of cultured podocytes with 100 mg/ml PAN for
24 h resulted in process retraction, cell rounding, and
detachment. Increasing dose and duration of PAN enhanced
podocyte injury. Pio ameliorated, but did not prevent, PAN-
induced morphologic injury (cells with differentiated foot
processes; baseline or Pio alone 100%, PAN 3376% vs
PANþ Pio 5971%) (Figure 1). This protective effect of Pio
was investigated by immunofluorescent staining with synap-
topodin. At baseline (Figure 2), differentiated podocytes
strongly expressed synaptopodin, a sensitive and specific
marker for differentiated podocytes,17 particularly in the
cytoplasm and extending toward cell processes. In contrast,
synaptopodin staining was decreased in PAN-treated podo-
cytes, largely reflecting decreased processes. Thus, foot
processes and corresponding synaptopodin protein expres-
sion were partially restored by adding Pio to injured
podocytes.
Apoptosis and necrosis
To investigate podocyte apoptosis induction by PAN, we
measured DNA fragmentation, a marker of the late stage of
apoptosis (Figure 3). Addition of Pio appeared to decrease
DNA fragmentation in response to PAN. Injury after PAN
treatment was also assessed by the terminal deoxynucleotidyl
transferase-mediated dUTP nick-end labeling method, with
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Figure 1 | Podocyte morphology. Fully differentiated cells were
exposed for 24 h to vehicle (0.02% DMSO), 100 mg/ml PAN, 0.1mM Pio,
or 0.1mM Pioþ 100mg/ml PAN as indicated. Differentiated podocytes
(a) demonstrated fine processes with interdigitations between cells.
Treatment with PAN (b) was associated with varying degree of
process retraction, cell rounding, and detachment. Podocytes treated
with 0.1mM Pio alone (c) showed no change in morphology compared
with normal control. However, adding Pio (d) partially prevented the
morphologic changes induced by PAN treatment, with more complex
processes and interdigitations.
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Figure 2 | Podocyte differentiation. (a) Podocytes treated with
vehicle strongly expressed synaptopodin, particularly in the
cytoplasm and extending toward cell processes. (b) Podocytes
treated with 100mg/ml PAN had markedly decreased foot processes
with corresponding decrease in synaptopodin in most cells, with
decreased staining of the retracted processes. (c) Podocytes treated
with 0.1 mM Pio alone showed no change in extent of foot processes
or synaptopodin compared with normal control. (d) Podocytes
treated with 0.1 mM Pioþ 100mg/ml PAN showed partial maintenance
of foot processes and corresponding synaptopodin staining, when
compared with PAN (anti-synaptopodin immunofluorescence,
original magnification  400).
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Figure 3 | DNA fragmentation in PAN-injured podocytes. Fully
differentiated cells were exposed to 0.1 mM Pio and injured with
variable concentrations of PAN (5, 30, and 100 mg/ml) for 24 h at 371C.
At the end of the incubation period, cells were prepared for DNA gel
electrophoresis. Lanes 1 and 10 show molecular weight markers.
Control (lane 2), 5 mg/ml PAN, (lane 3), and 5 mg/ml PANþ 0.1 mM Pio
(lane 6) did not show any DNA fragmentation, whereas 30 and
100 mg/ml PAN (lanes 4 and 5, respectively) showed DNA ladder
pattern reflecting intranucleosomal-DNA-fragment production. The
laddering was fainter when PAN-injured cells also were treated with
Pio (lanes 7 and 8) compared with PAN alone at same concentrations
(lanes 4 and 5).
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no positivity in normal cells, but frequent positivity after
PAN, and apparent decrease with added Pio (data not
shown). We then quantitated apoptotic changes by assessing
an early marker of these events, Annexin V. When cells
undergo apoptosis, phosphatidylserine residues relocate to
the outside of the cell membrane, which can be detected by
adding the specific binding molecule, Annexin V (Figure 4).
PAN induced significant apoptosis compared with untreated
cells, and Pio significantly attenuated PAN-induced apoptosis
(% cells apoptotic: CONT 10.471.7, PAN 20.172.4,
PANþ Pio 14.571.2, and Pio 9.571.5, Po0.01 PAN vs
dimethylsulfoxide (DMSO) control and PANþ Pio) and
necrosis (% cells necrotic: CONT 0.170.0, PAN 4.471.0,
PANþ Pio 1.070.6, and Pio 0.170.0). Again, Pio alone did
not affect apoptosis and necrosis in normal podocytes.
Lactate dehydrogenase release, a marker of cell necrosis, was
increased after PAN, with no effect of Pio (DMSO
4.371.5 U/L, PAN 21.777.0, Pio 7.371.5, PANþ Pio
21.775.7, Po0.01 PAN vs DMSO).
Corresponding to these changes in apoptosis, there was an
increase of Bax and decrease of Bcl-xL and Bcl-2 mRNA in
response to PAN (Figure 5). Pio had no significant effect on
Bax or Bcl-2 expression, but did increase Bcl-xL expression
(Bax mRNA expression, fold changes vs CONT: CONT
170.11, PAN 1.5670.28, PANþ Pio 1.5970.43, Pio
1.4870.50; PAN vs CONT Po0.01, PAN vs PANþ Pio
P¼ 0.88; Bcl-xL mRNA expression, fold changes vs CONT:
CONT 170.07, PAN 0.5670.07, PANþ Pio 0.7770.12, Pio
1.6270.72, Po0.01 PAN vs CONT and PANþ Pio; Bcl-2
mRNA expression, fold changes vs CONT: CONT 170.12,
PAN 0.5070.08, PANþ Pio 0.5670.13, Pio 0.8370.24,
Po0.01 PAN vs CONT, P¼NS PANþ Pio vs PAN).
We next assessed whether these changes in mRNA of
regulatory molecules of apoptosis affected protein expression
of a key downstream effector of apoptosis, cleaved caspase-3.
Activated caspase-3 was not detected at baseline, but was
markedly increased after PAN injury, and significantly
ameliorated by adding Pio (activated caspase-3/b-actin:
control with DMSO 0.1170.05, PAN 0.5970.14, Pio
0.0770.02, PANþ Pio 0.2970.02, Po0.01 PAN vs DMSO,
and Po0.05 PANþ Pio vs PAN) (Figure 6). Interestingly,
total caspase-3 displayed similar expression patterns after
PAN with or without Pio treatment as activated caspase-3.
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Figure 4 | Apoptosis in PAN-injured podocytes. Fully differentiated
podocytes were exposed for 24 h to vehicle (0.02% DMSO), 100mg/ml
PAN, 0.1mM Pio, or 0.1mM Pioþ 100 mg/ml PAN as indicated. Cell
aliquots were stained with Annexin V-FITC and PI and analyzed by
FACScan. Percentage of cells undergoing apoptosis was calculated
by percentage of cells staining with Annexin V-FITC and excluding
the PI dye.
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Figure 5 | Apoptotic regulatory molecule mRNA expression in
podocytes. Total RNA from podocytes was harvested and Bax, Bcl-xL,
and Bcl-2 mRNA expressions measured by quantitative real-time
PCR. Antiapoptotic molecules Bcl-xL and Bcl-2 were downregulated
after injury with PAN, whereas proapoptotic Bax was increased.
Added Pio significantly increased Bcl-xL.
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Figure 6 | Activated caspase-3 expression in podocytes. Protein
from podocytes was analyzed by Western blot for total and
cleaved-activated caspase-3. Activated caspase-3 was not detectable
under baseline conditions, but was markedly increased after PAN
injury, and ameliorated by added Pio.
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Effect of pioglitazone on PPAR-c expression and activity
Quantitative real-time polymerase chain reaction (PCR) was
used to assess podocyte expression of PPAR-g (Figure 7). At
baseline, podocytes expressed low level of PPAR-g mRNA,
which was decreased after exposure to PAN. Pio upregulated
PPAR-g expression both in control and PAN-injured cells,
largely preventing the PAN-induced decrease in PPAR-g
(mRNA expression, fold increase vs CONT: CONT 170.13,
PAN 0.5070.03, PANþ Pio 0.7470.30, Pio 1.7670.70,
Po0.05 Pio vs PAN). We then examined the activity of
PPAR-g as a transcription factor using a luciferase reporter
plasmid containing a PPAR-g response element. PAN only
numerically decreased PPAR-g activity (27% decrease in
luciferase vs control, pNS). In contrast, Pio resulted in
increased mRNA and activated PPAR-g (fold activation:
CONT 170.14, PAN 0.7370.19, PANþ Pio 1.5370.46, Pio
1.8070.12, Po0.01 PANþ Pio and Pio vs PAN) (Figure 8).
Cellular proliferation and cell cycle and TGF-b regulation
As expected, PAN not only induced cell necrosis and
apoptosis, but decreased cell proliferation, which was
restored by adding Pio to injured podocytes, while adding
Pio to normal podocytes had no effect (c.p.m.: CONT
2846171387, PAN 102707304, PANþ Pio 173957687, Pio
276027299, Po0.01 PAN vs CONT and PANþ Pio). To
investigate possible mechanisms of PPAR-g effects on
podocyte injury, apoptosis, and cell proliferation, we assessed
the CKIs p27, p21, and p57 using quantitative real-time PCR.
p27 was significantly downregulated after injury with PAN
(46% of control, P¼ 0.02) and expression was significantly
restored after combined treatment with PAN and Pio. In
contrast, p21 was changed only numerically, with increase
after exposure to PAN and PANþ Pio, and decrease with Pio
alone. p57 mRNA was not significantly affected. PAN
activated TGF-b in a dose-dependent manner (data not
shown), and there was a trend for attenuation by Pio (TGF-b
mRNA expression, fold increase vs CONT: CONT 1.070.15,
PAN 1.870.49, PANþ Pio 1.070.05, Pio 0.8570.03,
P¼ 0.07 PANþ Pio vs PAN).
DISCUSSION
In this study, we show that PPAR-g was expressed in both
normal and injured podocytes. Moreover, we demonstrated
that PPAR-g is downregulated at the mRNA level following
injury with PAN, and that treatment with the thiazolidine-
dione pioglitazone numerically increased PPAR-g mRNA and
significantly increased its activity. Pioglitazone also decreased
morphological cell injury, necrosis and apoptosis, decreased
activated caspase-3, and restored normal proliferation.
Possible mechanisms implicated by our further studies
include restored expression of a key CKI, p27, and the
antiapoptotic Bcl-xL, with decreased TGF-b. These data
implicate increased PPAR-g activation as a key protective
mechanism in podocyte injury.
The podocyte is a highly specialized cell with limited
capacity for proliferation.2 Mechanisms of podocyte loss and
restoration of injured podocytes are therefore key for
determining whether injury leads to progressive glomerulo-
sclerosis.18–20 In this in vitro system, we induced injury to
podocytes with the epithelial toxin PAN.21,22 PAN in vitro
results in foot process retraction and variable dose-dependent
cell death. In vivo, PAN induces injury in rats, which,
depending upon dose and route of administration, results in
minimal change disease or FSGS.12,23,24 Thus, both in vivo
and in vitro PAN-induced injury models are relevant for
understanding mechanisms of podocyte injury. As described
previously, podocytes showed altered morphology and
apoptosis and necrosis when exposed to this dose (100 mM)
of PAN.21 Of note, we chose a dose with only modest
lethal effects on cells, so that we might study the injury and
repair response. The podocyte injury was associated with
dedifferentiation of podocytes, as seen by decreases in foot
process formation with corresponding decrease in immu-
nostaining for synaptopodin, and marked decrease in
proliferation. Further, the CKI p27, but not p21 or p57,
was significantly downregulated in response to PAN, with
increase in TGF-b mRNA. The PPAR-g agonist pioglitazone
largely restored these abnormal responses, decreasing necro-
sis and apoptosis, and restoring differentiation and prolifera-
tion to normal levels. That these effects of pioglitazone were
mediated by specific PPAR-g actions was verified by increased
PPAR-g transcription factor activity. Increased PPAR-g
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Figure 7 | PPAR-c mRNA expression in podocytes. Total RNA from
podocytes was harvested and PPAR-g mRNA measured by
quantitative real-time PCR. PPAR-g mRNA was present in normal
podocytes treated only with vehicle (DMSO), and was decreased by
PAN. Pio increased PPAR-g mRNA.
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Figure 8 | Ligand-induced transcriptional activity of PPAR-c.
Transient transfection of differentiated podocytes was done using
Superfect reagent with PPAR response element 3-TK-luciferase. Cells
were subsequently incubated with control vehicle (DMSO) or
100mg/ml PAN70.1 mM Pio for 24 h. Luciferase activities in cell lysates
were measured using a luminometer. Results are expressed as ratio
to control. Pio increased PPAR-g activity both in normal and in
PAN-injured podocytes.
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activity was associated with restoration of p27 and Bcl-xL
mRNA levels, with decreased activated caspase-3 and
attenuated TGF-b.
Podocyte growth and apoptosis are complexly regulated.2
Bcl-2 family proteins include both proapoptotic molecules
such as Bax and antiapoptotic molecules such as Bcl-xL and
Bcl-2. These molecules are regulators of caspases, which serve
as terminal effector molecules in many types of apoptosis. In
previous studies, the group of Shankland examined cultured
podocytes injured by PAN and response to dexamethasone.25
Dexamethasone was effective in decreasing PAN-induced
apoptosis and increased Bcl-xL expression along with a
decrease in p53. In our studies, we observed similar
alterations in Bcl-xL in response to PAN, with normalization
by pioglitazone. Further, these changes were accompanied by
increase in the key downstream effector of apoptosis,
activated caspase-3, in response to PAN, with decrease by
added pioglitazone. The potential beneficial impact of
pioglitazone on podocyte injury is important, as dexametha-
sone has numerous side effects, which may limit its long-
term utility in vivo as a modulator of podocyte injury and
apoptosis. In our previous in vivo studies of PAN-induced
FSGS, we found very low expression of PPAR-g in normal
kidneys, with increased PPAR-g when injury was estab-
lished.12 This increased PPAR-g immunostaining was parti-
cularly evident in podocytes and mesangial cells in
segmentally sclerotic glomeruli. Treatment with a PPAR-g
agonist ameliorated progressive sclerosis, associated with a
strong accentuation of podocyte immunohistochemical
staining for PPAR-g.12 Our in vitro results support that
augmented PPAR-g protein could be a counterregulatory
response to injury that induces increased PPAR-g activation,
with beneficial responses on podocyte differentiation and
growth, with resulting decreased podocyte injury, and
increased survival. Indeed, treatment with pioglitazone in
the in vivo PAN model led to higher number of preserved
podocytes, as judged by glomerular WT-1-positivity, com-
pared with the untreated PAN-FSGS rats.
In additional in vitro studies, we examined if the restored
proliferation in response to pioglitazone was linked to effects
on CKIs. The podocyte highly expresses several such cyclin-
dependent kinase inhibitors, including p21, p27, and p57.2,25
However, only p27 was significantly affected in this PAN
injury model. p27 expression was significantly restored by
pioglitazone, associated with restoration of proliferation. Of
note, these responses of the podocytes were also associated
with alterations in TGF-b. TGF-b has numerous functions,
including key effects on cell growth/differentiation, immune
regulation, and matrix synthesis. In previous studies,
conditionally immortalized podocytes had induction of G0/
G1 arrest by autocrine TGF-b2 production.8 Differentiation
was also arrested. These effects were mediated through Smad-
3-dependent induction of the CKI p15. TGF-b effects on
podocytes were concentration-dependent, with distinctly
different signaling profiles at low vs high levels. At lower
levels, TGF-b induced G0/G1 arrest and differentiation of
podocytes, whereas higher concentrations were associated
with G2/M block and apoptosis.8 We found in our present
studies that TGF-b was increased in PAN-injured podocytes,
associated with apoptosis similar to these previously reported
results. Treatment with pioglitazone tended to attenuate this
change, with TGF-b mRNA expression returning towards
control baseline. PPAR-g has numerous effects on a variety of
genes, and is a key molecule linked to progressive sclerosis.
We have previously observed in the hypertensive 5/6
nephrectomy model of FSGS that PPAR-g agonists could
decrease the upregulated TGF-b and PAI-1.11 However, in
our studies of the PAN model of sclerosis with minimal
hypertension, we did not observe significant changes of TGF-
b at the whole kidney level.12 The current in vitro data
indicate that local cell-specific podocyte alterations in TGF-b
may occur in the PAN model of FSGS, and may influence
podocyte apoptosis vs growth and differentiation. Further,
PPAR-g agonist may dampen such deleterious podocyte
upregulation of TGF-b.
In summary, pioglitazone is effective in decreasing
podocyte injury in vitro, with possible mechanisms including
decreased apoptosis with decreased activated caspase-3,
restoration of the key CKI p27 and Bcl-xL, and decreased
TGF-b. Taken together with our recent in vivo observations,
these data suggest the potential for thiazolidinediones as a
therapeutic strategy in podocyte-related diseases.
MATERIALS AND METHODS
Cell culture
Studies were performed in a conditionally immortalized mouse
podocyte cell line as described previously.26 These cells carry a
thermosensitive variant of the SV-40-T-antigen, which is under the
control of the H-2Kb-promoter. Activity of this promoter can be
enhanced by interferon-g. Briefly, the cells were grown in type I
collagen-coated flasks and propagated at 331C in RPMI-1640 media
(Gibco/Life Technologies, Grand Islands, NY, USA) containing 10%
heat-inactivated fetal calf serum (Hyclone, Logan, UT, USA), 100 U/
ml penicillin (Sigma, St Louis, MO, USA), 100mg/ml (Sigma), and
10 U/ml interferon-g (Sigma) to induce synthesis of the immortaliz-
ing T antigen. Subcultivation was done by disaggregation with 0.1%
trypsin–0.01% EDTA (Sigma) in Hanks’ balanced salt solution
(Sigma) at 371C after cells had reached confluence. Cells were
passaged after 1:5 dilution. To initiate differentiation, cells were then
plated in collagen type I-coated flasks under nonpermissive
condition (371C without interferon-g) for at least 7 days with
medium change every 3 days.
Experimental design
To determine the role of PPAR-g in injured podocytes, fully
differentiated podocytes cultured for 7–10 days at 371C, were treated
with PAN (100 mg/ml)22,27 in the presence or absence of the PPAR-g-
specific agonist pioglitazone (0.1 mM, Pio, Takeda, Lincolnshire, IL,
USA) for 24 h. This dose of Pio was based on pilot studies that
showed that this dose had the maximum protective effect against
PAN-induced podocyte injury. Effects of PPAR-g on cell injury, cell
cycle, differentiation, and TGF-b were then assessed in fully
differentiated cells. All data are based on results from at least three
independent experiments, unless otherwise indicated.
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Analysis of cell morphology
Podocyte morphology was assessed qualitatively and quantitatively
by examining the extent of foot process formation, determined as
number of processes per cell, and percent of cells with processes
longer than cell body diameter, determined from images of stained
cells. For indirect immunofluorescence, cells cultured on collagen
type I-coated chamber slides were fixed with 2% paraformaldehyde
and 4% sucrose in phosphate-buffered saline (PBS) for 5 min at
room temperature followed by permeabilization with 0.3% Triton
X-100 in PBS for 5 min. After rinsing with PBS, cells were incubated
with 2% fetal calf serum, 2% bovine serum albumin, and 0.2% fish
gelatin in PBS for 1 h. Cells were then incubated with monoclonal
mouse anti-synaptopodin antibody (Progen, Heldelberg, Germany)
overnight at 41C, followed by fluorescein isothiocyanate (FITC)-
conjugated anti-mouse immunoglobulin G antibody (Vector,
Burlingame, CA, USA). Cells were subsequently mounted in 15%
Mowiol (Calbiochem, San Diego, CA, USA) and 50% glycerol in
PBS. Normal mouse serum was used in place of specific antibody as
a negative control, and showed no staining. Images of immuno-
fluorescent cells were captured with the AxioVision software
program using a Zeiss AxioCam camera attached to a Nikon Eclipse
E400 microscope (Nikon Instruments, Inc., Melville, NY, USA).
Apoptosis and necrosis
DNA fragmentation was assessed by agarose gel electrophoresis
performed on fully differentiated cells exposed to a dose range of
PAN (5, 30, or 100mg/ml) with or without Pio (0.1 mM) for 24 h at
371C. At the end of the incubation period, adherent and floating
cells were prepared for DNA isolation using column purification
(Roche, Indianapolis, IN, USA) and DNA was subjected to
electrophoresis on 1% agarose gels. The gel was examined and
photographed under ultraviolet light. The terminal deoxynucleoti-
dyl transferase-mediated dUTP nick-end labeling method was also
used. The 30-OH ends of fragmented DNA were directly labeled with
tetramethylrhodamine red (TMR) red-labeled dUTP by terminal
deoxynucleotidyl transferase (Roche). All nuclei were counterstained
with Hoechst 33258 (Sigma) and terminal deoxynucleotidyl
transferase-mediated dUTP nick-end labeling-positive and -negative
nuclei were assessed under a fluorescence microscope with similar
density of cells in each field viewed.
We next quantified apoptosis by assessing propidium iodide (PI)
and Annexin V. Cells were seeded onto culture dishes at a density of
1000 cells/cm3, allowed to fully differentiate and treated with PAN
with or without Pio as described above. Cells were then washed
twice with ice-cold PBS, trypsinized, neutralized with serum, and
pelleted by centrifugation at 200g for 5 min. The pellets were washed
once with PBS, transferred to 5 ml culture tubes and resuspended in
2 ml of PI dye and 2 ml of Annexin V-FITC (Roche). Four hundred
microliters of 1 binding buffer were added to each tube and
FACscan analysis of the samples was performed within 1 h using a
FACS scan equipped with Cell Quest software (BD Biosciences, San
Jose, CA, USA). The following controls were used to set up
compensation and quadrants: (1) unstained cells, (2) cells stained
with Annexin V-FITC alone, (3) cells stained with PI alone, and (4)
cells stained with both Annexin V-FITC and PI. Exclusion of PI
coupled with binding of Annexin V-FITC indicates an apoptotic cell,
whereas double-positive or double-negative staining indicates
necrotic cells or living cells, respectively. The percentage of cells
undergoing apoptosis in response to experimental maneuvers was
determined by correcting for apoptosis and necrosis under baseline
control conditions. Experiments were repeated three times.
Cells treated as above with DMSO, PAN, PAN with Pio, or Pio
alone were assessed for lactate dehydrogenase release. Culture
medium was collected and centrifuged, and the supernatant
analyzed for lactate dehydrogenase activity using the lactate
dehydrogenase IFCC liquid method (Roche Diagnostics).
Cell proliferation
Cell proliferation was assessed in cells treated as above by measuring
the incorporation of 3H-thymidine. In brief, 2500 cells were plated
onto 96-well plates in complete medium, and differentiation was
induced as above. Cells were then exposed to a dose range of PAN
alone or with Pio as above, and 1 mCi of 3H-thymidine was added,
and cells incubated at 371C for 24 h before harvest.28 Cells were then
washed three times with PBS, lysed with 100ml 1% sodium dodecyl
sulfate and the amount of 3H-thymidine counted using a b-counter.
Cell transfection
To assess the extent of PPAR-g activation, cells seeded at densities of
1000 cells/cm3 in 6-well plates and then fully differentiated, were
transiently transfected with the PPAR response element 3-TK-
luciferase vector, a reporter construct with a PPAR-g response
element derived from the PPAR-g target gene acyl-CoA oxidase.29
PPAR-g-mediated promoter activation was then assessed using
Superfect reaction (QIAGEN, Valencia, CA, USA) according to the
developer’s instruction. The cells were simultaneously cotransfected
with the phRL-TK vector, a Renilla luciferase–thymidine kinase
plasmid (Promega, Madison, WI, USA) as control to assess
transfection efficiency. Cells were then treated as above for 24 h
with a dose range of PAN with or without Pio. Firefly and Renilla
luciferase activities in cell lysates were then measured (Promega
assay kit). Luciferase activity was measured using a TD-20/20
luminometer. To correct for differences in transfection efficiency,
firefly luciferase units were normalized for Renilla luciferase activity
Table 1 | Primer and probe sequences
Name
DNA sequence from 50–30
Forward primer Probe Reverse primer
PPAR-g CTGTTATGGGTGAAACTCTGGGAG 6FAM-TCCTGTTGACCCAGAGCATGGTGC-TAMRA ATAGGCAGTGCATCAGCGAA
TGF-b GCAACATGTGGAACTCTACCAGAA 6FAM-ACCTTGGTAACCGGCTGCTGACCC-TAMRA GACGTCAAAAGACAGCCACTCA
P21 CCGTTGTCTCTTCGGTCCC 6FAM-TGGACAGTGAGCAGTTGCGCCG-TAMRA CATGAGCGCATCGCAATC
P27 TTTTCCGGAGAGAGGCGAG 6FAM-CGGTGGTCCACACCCGCCC-TAMRA CTCACGTTTGACATCTTCCTCCT
P57 CAGCGGACGATGGAAGAACT 6FAM-TGGGCTTCGGCTGGGACCTTTC-TAMRA CTCCGGTTCCTGCTACATGAA
Bcl-2 CTGAGTACCTGAACCGGCATC 6FAM-CCCCAGCATGCGACCTCTGTTTG-TAMRA GAGCAGCGTCTTCAGAGACAG
Bcl-xL TGACCACCTAGAGCCTTGGAT 6FAM-CGGGAACAATGCAGCAGCCGAG-TAMRA CAGGAACCAGCGGTTGAAA
Bax GTTTCATCCAGGATCGAGCAG 6FAM-AGCTGAGCGAGTGTCTCCGGCG-TAMRA AGCTGAGCGAGTGTCTCCGGCG
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in the same lysate. The normalized readings were subtracted with
empty vector readings.
Real-time quantitative reverse transcriptase-polymerase
chain reaction
Total RNA was extracted from cells as previously described11.
Quantitation of gene expression was performed by real-time
quantitative reverse transcriptase-polymerase chain reaction using
the ABI PRISMs 7700 Sequence Detection System (PE Applied
Biosystems, Foster City, CA, USA). A 25-ml PCR reaction mixture
containing 1 ml of cDNA, 1 TaqMan PCR Master Mix (PE Applied
Biosystems), 810 ng of gene-specific forward and reverse primers
and 6.25mM of the corresponding real-time PCR probe at final
concentrations was used. Primers and probes designed to target
mouse PPARg, p21, p27, p57, Bax, Bcl-2, Bcl-xL, and TGFb are
listed in Table 1. The reaction conditions were designed as follows:
initial denaturation at 951C for 10 min followed by 40 two-step
cycles with 30 s at 951C for denaturing and 1 min at 601C for annealing
and extension. The threshold cycle, that is the cycle number at which
the amount of amplified gene of interest reached a fixed threshold, was
subsequently determined. Relative quantification of each target mRNA
level was normalized to 18S rRNA and calculated by the comparative
threshold cycle method described elsewhere.30
Western blot of activated caspase-3
Cells treated as above with DMSO, PAN with or without Pio, or Pio
alone (including floating cells) were harvested and lysed in modified
radioimmunoprecipitation assay lysis buffer with protease and
phosphatase inhibitors as described previously.31 Protein samples
(30mg) were separated on 12% sodium dodecyl sulfate-polyacryla-
mide gel electrophoresis, transferred to a polyvinylidene difluoride
membrane, blocked in 5% non-fat dried milk in Tris-buffered saline
Tween (TBS and 0.01% Tween 20), and incubated overnight (41C)
with the following primary antibodies: anti-cleaved caspase-3
antibody (Asp175, Cat#9661, Cell Signaling Technology, Danvers,
MA, USA) or anti-caspase-3 antibody 1:500 (Cat no. 9662, Cell
Signaling). After washing, secondary antibody was added and
incubated 1 h at room temperature and protein bands were
visualized by ECL Plus (Amersham, Arlington Heights, IL, USA).
The membranes were then stripped and re-probed with mouse anti-
b-actin antibody (Sigma). Densitometric quantitation was per-
formed using NIH image (version 1.63). Protein expression was
quantified as the ratio of specific band to b-actin. Experiments were
performed and repeated independently twice.
Statistical analysis
Data are presented as means7s.e.m., unless otherwise noted. P-
values were calculated by analysis of variance followed by unpaired
t-test with correction for multiple comparisons as appropriate. A
Po0.05 was considered to be significant.
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